Thank you for subscribing!

Addressing Holistic Health Through Multiple Market Applications

The world views healthcare differently than it did before March of 2020. Consumers, businesses, healthcare providers, and the entire global industry has been given the opportunity to not just examine the in-patient and pharmaceutical aspects of healthcare, but also the day-to-day products, services, and structures that support overall health. 

Rayont Inc. (OTCMKTS: RAYT) is an international healthcare company “making natural products to improve people’s health,” building an impressive portfolio of subsidiaries and products that address therapeutic needs, alternative treatments, nutrition, supplementation, as well as investing in exciting cancer treatments, and much more.


Key Investment Considerations 

Positive Balance Sheets Results – Rayont has shown consistent improvement and growth on their balance sheets. The company proudly acknowledges its 200% growth, which they believe they can sustain through acquisitions, expansion, and digitization. 

Inclusion in Multiple Markets – Brands under Rayont’s umbrella address holistic and non-traditional approaches to health. This casts a wide net for reaching various consumers across the globe, all spanning the full spectrum of health and wellness. 

Capitalizing on an Evolving Healthcare MarketThe global complementary and alternative medicine (CAM) market is growing considerably. It’s projected to top $411B by 2030, largely on the shoulders of research and treatments addressing neurological disorders and cancer. Rayont has invested in the latter as the exclusive distributor of Photosoft, a Next-Generation Photo Dynamic Therapy for treating a wide range of cancers.  


Sustaining 200% Growth 

The bottom line speaks volumes for any investment and Rayont shareholders have enjoyed the sound of earnings reports for some time now. 

The nine months ending June 30 saw revenue jump from 1.27M to 2.24M between 2020 and 2021, and gross profit grew $379K to 1.26M in the same period. The six months ending December 31 saw revenue increase from 1.19M to $1.36M in 2020 to 2021, and profits increased $524k to $690k in the same period. This is just a small bit of Rayont’s full financial history, but it’s representative of consistent growth the company believes they will sustain. In 2018 the company reported $23k in gross profit, for example, which had grown to $671k for the six months ending December 31, 2021. Rayont has enjoyed consistent growth and delivered consistent value to its shareholders — markers of a well-run business positioned for further potential expansion.

So, let’s dig into where this growing business operates…  

CAM: A Booming Sector of Healthcare

Grandview Research estimates the global complementary and alternative medicine (CAM) market size was valued at USD 82.27B in 2020 and is expected to expand at a CAGR of 22.03% from 2021 to 2028. This can include products and services that focus on the use of vitamins, minerals, herbal, aromatherapy or homeopathic products or services as alternative treatment to conventional or mainstream medicines. And it can be big business because these treatments don’t fall under traditional health insurance coverages. This out-of-pocket structure ensures successful CAM businesses prioritize quality products, services, and investing in research to support each. CAM businesses can work to earn customer/brand loyalty that doesn’t exist in standard biotech/pharma. 

The Vitamins and Supplements Opportunity 

Supplementation is a big piece of the health and wellness industry puzzle. Everywhere from supermarkets to pharmacies, nutritional specialty stores, and ecommerce have all seen steady increases in product sales in this category, which accounted for $168B in 2020. That number is now expected to reach $307B by 2028, experiencing a CAGR of 8.9%. 

“Consumers are anticipated to continue using vitamins and supplements to complement their diets and exercise routines,” Rayont wrote before the COVID-19 pandemic began. “Asian markets, particularly China, are expected to offer significant growth opportunities, as their middle class consumes more imported goods and focuses more on health-related issues.” 

This prediction certainly came true. In the United States, for example, dietary supplement sales increased by 5% leading up to the beginning of the pandemic. There was an immediate 44% increase in April 2020, while the UK saw a 63% increase in March and 40% – 60% in France. While that spike may have been temporary, consumers have settled into a “new normal,” with VMS sales still growing at rates higher than the 5% pre-pandemic rate. 

Rayont’s Premalife product offerings are targeted for global expansion in this market. Its Wonderfoods online store offers OTC/ecommerce products, while its HealthScript platform makes prescription-only products available through more than 2,000 licensed naturopaths in Australia carrying and distributing their products.

A Long Term Investment In Cancer Treatment 

Photo Dynamic Therapy (PDT) is a competitive market within the business of cancer treatment. PDT drugs are light-sensitive drugs, activated with the use of specific lights in order to attack and kill certain cancer cells. 

The demand for this type of treatment pushed its market value to $3.96B in 2021 and is projected to reach $7.1B in 2025, growing at a CAGR of 15.7%. 

Rayont’s investment in this treatment includes the exclusive distribution and licensing of PhotoSoft, a Next Generation Photo Dynamic Therapy (NGPDT) in South Africa and Sub-Saharan Africa.  


Rayont’s Product and Service Offerings

Rayont delivers products primarily for consumers who are health conscious, middle income, shop online, and require personalized guidance by a registered naturopath or health coach. The company divides these products and services into five specific segments: 

  • Health Literacy – Doctor as the Teacher

  • Organic Food – Food is the Medicine

  • Customized organic food, nutraceutical products and services to their
    needs based on AI and Naturopaths Recommendations

  • Remedial Message and Physio Therapy Services

  • Access to Affiliate Network of CAM Practitioners Globally

Diverse Brands

No More Knots

No More Knots is a wholly owned subsidiary of Rayont, which specializes in remedial massage and myotherapy in Australia.  

Next Generation, Photo Dynamic Therapy (NGPDT) 

NGPDT is an innovative therapy designed to treat a wide range of cancers, including skin cancers and solid tumors. NGPDT uses an advanced formula of Photosoft, which Rayont is the exclusive distributor of. 

NVA, Complementary and Alternative Medicine Contract Manufacturing 

Natural Vitality Australia manufactures high quality health products, including its Wonder Foods brand.  

Wonderfoods, Complementary & Alternative Medicine eCommerce

Wonder Foods is an ecommerce platform that delivers supplements as well as complementary and alternative medicines. 

Healthscript, Telehealth Platform for Naturopaths

Healthscript is a platform that enables consumers to find, consult, and obtain prescriptions from licensed naturopaths online or on their mobile phones.  

Total Vita, Health Education 

Total Vita is a health literacy and education platform for consumers. 

NPM, Prescription Only Complementary Alternative Medicine 

Natura is a brand of products that licensed naturopaths can prescribe to patients. It currently has more than 2,000 licensed naturopaths in Australia carrying and distributing the company’s products. 

Rosa Naturels, Cosmetics 

Rosa Naturel is a cosmetic range distributed online and in pharmacies across Australia.


Press Releases 



Marshini Moodley, President and CFO 

Marshini Moodley has a strong corporate background in finance and management that includes over 20 years of professional services for companies in healthcare, education, real estate, retail, and technology. The ongoing diversification of Rayont’s holdings provides a unique opportunity for Her vision of Rayont becoming a world leader Private Equity firm. Previously, Marshini was the  CFO   for a number of private funds such as Future Asset Management International Ltd and Zenio Capital Ltd.

Mark Van Wyk, Independent Director 

Mark is a seasoned business leader and strategist with a diverse 37-year career across several industry sectors including health and aged care services, community services, environmental , financial and professional services, engineering, infrastructure, mining/resources, construction, manufacturing, building services and agriculture. 



Who are we and what do we do? We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (the “Information”) about publicly traded companies (the “Profiled Issuers”). How is the Information published? We publish the Information on our Website, in newsletters, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer or third party paying us. Our publication of the Information is known as a “Campaign”. Will everyone receive the Information at the same time? No. The Information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. How is a potential investor impacted if he/she receives the Information later than other investors? Typically, the trading volume and price of a Profiled Issuer’s securities increases after the Information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he/she may suffer increased trading losses if he/she purchases the securities of a Profiled Issuer. What will happen when the Campaign ends? Most, if not all, of the Profiled Issuers are penny stocks that are illiquid and whose securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profiled Issuer will likely increase significantly. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment. Why do we publish only favorable Information? We only publish favorable information because we are compensated to publish only favorable information. Why don’t we publish negative Information? We don’t publish negative information because we are not paid to publish negative information. We are paid to publish only favorable information. Is the Information complete, accurate, truthful or reliable? No. The Information is a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. What we do not do? We do not publish negative information about the Profiled Issuers. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities. Where does the Information come from? The Information is provided to us by the Profiled Issuers and/or the person who hires us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, the Securities and Exchange Commission’s Edgar database or other available public sources. If we say we make “stock picks,” are those picks our own? No, they are not. We are compensated to advertise the securities we are told to advertise. What will happen if an investor relies on the Information? If an investor relies on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision. Who pays us to publish the Information? The source of our compensation varies depending upon the particular circumstances of the Campaign. We are compensated by the Profiled Issuers, third party shareholders and other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities. The nature and amount of compensation we receive for publishing the Information about each Profiled Issuer and our ownership of each Profiled Issuer is set forth below under the heading captioned, “What we are compensated”. What warranties do we make about the Information? None. We make no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation. What we are not. We are not and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following:
  • An independent adviser or consultant;
  • A fortune teller;
  • An investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
  • A broker-dealer or an individual acting in the capacity of a registered representative or broker;
  • A stock picker;
  • A securities trading expert;
  • A securities researcher or analyst;
  • A financial planner or one who engages in financial planning;
  • A provider of stock recommendations;
  • A provider of advice about buy, sell or hold recommendations as to specific securities; or
  • An agent offering or securities for sale or soliciting their purchase.
Are risks in this disclaimer the only risks investors should be aware of? No. There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer. What conflicts of interest do we have in publishing the Information? We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. Our publication of the Information involves actual and material conflicts of interest including but not limited to the following:
  • We receive monetary and/or securities compensation in exchange for publishing the (favorable) Information about the Profiled Issuers;
  • We do not publish any negative information whatsoever about the Profiled Issuers;
  • We may own a Profiled Issuer’s securities that we acquired from the Profiled Issuer, third parties or from our own open market purchases before, during or after the Campaign and we may sell these securities during the Campaign while publishing the (favorable) information that instructs investors to purchase. Our selling of a Profiled Issuer’s securities will likely cause investors to suffer losses;
  • A short time after we acquire a Profiled Issuer’s payment via cash or securities, we may publish the (favorable) Information about the Profiled Issuer advising others, including you, to purchase; and while doing so, we may sell the Profiled Issuer’s securities we acquired during our public dissemination of the Information causing us to profit while you suffer a loss;
  • Parties holding a Profiled Issuer’s securities, including those who engage our services and/or compensate us, will sell their shares of the Profiled Issuer while we are publishing the (favorable) Information.
Who is responsible if an investor relies on the Information? The investor. We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions or errors in the Information, and we are not responsible for actions taken by any person who relies upon the Information. What do we urge potential investors to do? We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, OTC Markets, NASDAQ, NYSE, or other available public sources. Why is this Disclaimer being provided? We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose our compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell our own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns. What are other risks that investors should be aware of? Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.
  • We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.
  • If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
  • The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.
  • The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.
  • You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.
  • We or other stock promoters may receive free trading shares as compensation or we may acquire such shares in open market transactions before and during the Campaigns, and we may sell the shares we acquire at any time, even during the Campaigns while publishing the Favorable Information. When we sell the shares of the Profiled Issuers that we hold, the price at which investors can sell their shares will dramatically decrease and will likely cause investors to suffer trading losses.
  • We may sell securities of the Profiled Issuers for less than target prices set forth in the Information, and we may profit by selling our securities during the Campaigns while investors encounter losses.
  • When we acquire, purchase or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit us to make substantial profits while investors who purchase during the Campaign experience significant losses.
  • The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.
  • If we are compensated in improperly free trading securities of the Profiled Issuers, either directly or indirectly from persons who claim to be non-affiliates of such Profiled Issuer, we and the Profiled Issuer or third party could be subject to SEC Enforcement Action, including allegations of an illegal distribution in violation of Section 5(a) and 5(c) of the Securities Act.
  • We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and fail to disclose their compensation to you.
If a Profiled Issuer is an SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions. If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies. The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at, or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at and You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at What we were paid to advertise the Profiled Issuers. The details of our compensation and the period of the Campaign is set forth below.
  • Name of Issuer & Ticker Symbol - Rayont Inc. (RAYT)
  • Amount & Form of Compensation - $90,000 in USD
  • Who Paid for the Campaign & Position with Company if any - Rayont Inc. (RAYT)
  • Period of Campaign - 4/20/2022 - 7/20/2022

Related Post

Register to Download the Presentation

Go to website
Go to top